|
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
RECRUITINGPhase 2Sponsored by Tianjin ConjuStar Biologics Co., Ltd.
Actively Recruiting
PhasePhase 2
SponsorTianjin ConjuStar Biologics Co., Ltd.
Started2025-08-26
Est. completion2027-07-30
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07080619
Summary
This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria: Age between 18 and 75 years (inclusive), regardless of gender. ECOG performance status of 0-1. Expected survival of more than 3 months, as assessed by the investigator. Fertile participants must agree to use contraception. Able to understand the trial requirements and willing and able to comply with the trial and follow-up procedures. Adequate bone marrow and organ function. NECTIN-4 gene amplification positive. Exclusion Criteria: Unstable central nervous system tumors. Adverse reactions from previous anticancer treatments have not recovered to a CTCAE 5.0 grade ≤1. A history of severe cardiovascular or cerebrovascular disease.
Conditions4
Breast CancerCancerHR+ Breast CancerTNBC - Triple-Negative Breast Cancer
Interventions1
Related trials
- Study SC-101 in Subjects With Advanced Malignancies — Tianjin ConjuStar Biologics Co., Ltd.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorTianjin ConjuStar Biologics Co., Ltd.
Started2025-08-26
Est. completion2027-07-30
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07080619